RxDoctor Payments Data

Aleicia Mack, DO

Cardiovascular Disease · Oklahoma City, OKNPI 1629105879

Payments from drug & device makers

$4,838in general payments, 2019–2025

Across 313 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Novartis$873
  • Amgen$307
  • Boehringer Ingelheim$307
  • Pfizer$282
  • E.r. Squibb & Sons, L.L.C.$251
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,830100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,838 in reported general payments places this provider in the 60th percentile of 164 cardiovascular disease providers in Oklahoma.

See all cardiovascular disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$169,293
Medicare patients
1,521
Services billed
3,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban418$423,553
EntrestoSacubitril/Valsartan114$141,790
Repatha SureclickEvolocumab103$69,054
XareltoRivaroxaban32$34,450
JardianceEmpagliflozin21$27,092
BrilintaTicagrelor22$15,838
Praluent PenAlirocumab21$12,046
Metoprolol Succinate351$5,091
Atorvastatin Calcium323$4,996
Droxidopa18$4,575
Prasugrel Hcl38$4,195
Nebivolol Hcl45$3,363
Diltiazem 12hr ErDiltiazem Hcl13$3,018
Losartan Potassium184$2,906
Potassium Chloride240$2,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$282$423,553418 claims
NovartisEntresto$873$141,790114 claims
Johnson & JohnsonXarelto$208$34,45032 claims
Boehringer IngelheimJardiance$307$27,09221 claims
AstraZenecaBrilinta$54$15,83822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 164 cardiovascular disease providers in Oklahoma.

Other cardiovascular disease in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →